News Column

ENZON PHARMACEUTICALS INC FILES (8-K) Disclosing Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

May 9, 2014



Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On May 8, 2014, Enzon Pharmaceuticals, Inc. (the "Company") received a letter from the Listing Qualifications department of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that its application to transfer the listing of its common stock to the Nasdaq Capital Market has been approved. The Company's common stock will be transferred to the Nasdaq Capital Market at the opening of business on May 12, 2014 and will continue to trade under the symbol "ENZN."

As previously announced, on March 19, 2014, the Company received a letter from the Listing Qualifications department of Nasdaq notifying the Company that it no longer complies with the requirement to maintain a minimum of $10 million in stockholders' equity for continued listing on the Nasdaq Global Select Market. In lieu of seeking to regain compliance for continued listing on the Nasdaq Global Select Market, the Company applied to transfer the listing of its common stock to the Nasdaq Capital Market.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters